Skip to content

Article

Linden in Exclusivity to Buy ArtesRx; Antares in Talks to Lead Debt Financing

Share on X (opens in a new window) Share on Facebook (opens in a new window) Share on LinkedIn (opens in a new window)
✨ Summary by AI at Octus
Linden Capital Partners is in exclusive talks to acquire ArtesRx, a specialty pharmacy platform backed by Flexpoint Ford. Antares Capital is expected to lead the debt financing for the acquisition. ArtesRx, which generates approximately $60 million in EBITDA, was established by Flexpoint in 2023 through the acquisition of Parkview Health Services and has expanded through investments in True Health Investors and Monument Pharmacy. Recent transactions in the sector include WindRose Health Investors' sale of Altruix to Frazier Healthcare Partners, with Houlihan Lokey advising on both processes.

Reporting: Benjamin Taubman, Armie Margaret Lee, Aaron Weitzman

Linden Capital Partners is holding exclusive talks to acquire Flexpoint Ford-backed specialty pharmacy platform ArtesRx, according to sources.

Antares Capital is in discussions to lead the debt financing package to support the acquisition, one source said.

Octus reported in mid-June that ArtesRx was in the midst of a sale process, with Houlihan Lokey advising. The business generates roughly $60 million of EBITDA, as reported.

ArtesRx is a pharmacy platform that owns and operates businesses serving complex patient populations, including behavioral health and long-term care communities.

Flexpoint established the platform in 2023 through its acquisition of Amherst, N.Y.-based specialized pharmacy provider Parkview Health Services, which became the company’s founding business, according to a press release at the time.

The platform has since grown through investments in True Health Investors, a retail and long-term care pharmacy and medication adherence provider, as well as in Monument Pharmacy and Monument-Fairfax.

Recent deals in the sector include WindRose Health Investors’ sale of behavioral health pharmacy company Altruix to Frazier Healthcare Partners in May. The deal announcement came about one month after Octus reported that Frazier was nearing a deal to acquire the business, which generates roughly $40 million in EBITDA. Houlihan Lokey advised Altruix on the process, as reported.

Linden, a private equity firm based in Chicago, focuses on the healthcare industry. Earlier this month, Linden and Audax Private Equity agreed to sell StatLab Medical Products to Leica Biosystems, an operating company of Danaher Corp.

Healthcare companies currently exploring sales include Waud Capital Partners-backed Concierge Home Care, Octus reported. The company, which generates $25 million to $30 million in EBITDA, is running an auction with Harris Williams.

Elsewhere, Vistria Group-backed air ambulance provider Angel MedFlight is weighing a sale via Perella Weinberg Partners, Octus reported. The business generates roughly $70 million to $75 million of EBITDA.

Newly issued senior direct lending facilities to back leveraged buyouts in the healthcare sector widened to an average of SOFR+510 bps in the second quarter of 2026 from SOFR+492.19 bps in the first quarter, according to Octus’ Private Credit Dashboard.

Antares and Houlihan declined to comment. Linden, Flexpoint and ArtesRx did not immediately respond to requests for comment.

This publication has been prepared by Octus Intelligence, Inc. or one of its affiliates (collectively, "Octus") and is being provided to the recipient in connection with a subscription to one or more Octus products. Recipient’s use of the Octus platform is subject to Octus Terms of Use or the user agreement pursuant to which the recipient has access to the platform (the “Applicable Terms”). The recipient of this publication may not redistribute or republish any portion of the information contained herein other than with Octus express written consent or in accordance with the Applicable Terms. The information in this publication is for general informational purposes only and should not be construed as legal, investment, accounting or other professional advice on any subject matter or as a substitute for such advice. The recipient of this publication must comply with all applicable laws, including laws regarding the purchase and sale of securities. Octus obtains information from a wide variety of sources, which it believes to be reliable, but Octus does not make any representation, warranty, or certification as to the materiality or public availability of the information in this publication or that such information is accurate, complete, comprehensive or fit for a particular purpose. Recipients must make their own decisions about investment strategies or securities mentioned in this publication. Octus and its officers, directors, partners and employees expressly disclaim all liability relating to or arising from actions taken or not taken based on any or all of the information contained in this publication. © 2026 Octus. All rights reserved. Octus(TM) and the Octus logo are trademarks of Octus Intelligence, Inc.